ACETAZOLAMIDE SODIUM Drug Patent Profile
✉ Email this page to a colleague
When do Acetazolamide Sodium patents expire, and when can generic versions of Acetazolamide Sodium launch?
Acetazolamide Sodium is a drug marketed by Avet Lifesciences, Gland, Hikma, Hospira, Mylan Asi, Ph Health, Xgen Pharms, and Zydus Pharms. and is included in eight NDAs.
The generic ingredient in ACETAZOLAMIDE SODIUM is acetazolamide sodium. There are ten drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the acetazolamide sodium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Acetazolamide Sodium
A generic version of ACETAZOLAMIDE SODIUM was approved as acetazolamide sodium by HIKMA on February 28th, 1995.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for ACETAZOLAMIDE SODIUM?
- What are the global sales for ACETAZOLAMIDE SODIUM?
- What is Average Wholesale Price for ACETAZOLAMIDE SODIUM?
Summary for ACETAZOLAMIDE SODIUM
| US Patents: | 0 |
| Applicants: | 8 |
| NDAs: | 8 |
| Finished Product Suppliers / Packagers: | 6 |
| Raw Ingredient (Bulk) Api Vendors: | 1 |
| Clinical Trials: | 11 |
| Patent Applications: | 467 |
| DailyMed Link: | ACETAZOLAMIDE SODIUM at DailyMed |
Recent Clinical Trials for ACETAZOLAMIDE SODIUM
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Clinica Alemana de Santiago | NA |
| Sociedad Andaluza de Cardiologa | PHASE2 |
| Maimnides Biomedical Research Institute of Crdoba | PHASE2 |
Pharmacology for ACETAZOLAMIDE SODIUM
| Drug Class | Carbonic Anhydrase Inhibitor |
| Mechanism of Action | Carbonic Anhydrase Inhibitors |

